LATHAM, N.Y. March 29, 2010 - AngioDynamics (NASDAQ: ANGO) announced today the opening of its new corporate headquarters, based in the Albany region of New York State.

Seventy AngioDynamics employees are now based at the new three-story building, including President and CEO Jan Keltjens. Other departments at the new site include the Peripheral Vascular and Vascular Access Business Units, the Advanced Research & Development and Corporate Marketing departments, as well as corporate staff.

"The opening of our new corporate headquarters, along with the further development of our existing manufacturing facility in Queensbury, represents our continuing commitment to economic growth in this region," said Jan Keltjens, President and CEO of AngioDynamics. "In addition to taking full advantage of all the resources Tech Valley has to offer - including advanced centers of education like RPI and the UAlbany NanoCollege, and leading medical institutions such as Albany Med and Ellis Medicine - our new headquarters will be able to better leverage the nearby Albany International Airport, giving us the travel options our new global strategy demands and allowing us to build deeper connections with our customers."

The new location expands AngioDynamics' presence in the midst of Upstate New York's life sciences and medical device industry sector with its more than 100 companies in the space. The region benefits from more than 350,000 students and faculty at nearly 100 colleges and universities producing more than $2 billion in research annually.

"AngioDynamics is a shining example we are moving forward in New York today," said U.S. Sen. Charles Schumer, D-N.Y. "From its early days and roots in Queensbury, the stage is set for AngioDynamics to grow significantly - producing jobs and the next generation of innovative medical devices right here in the Capital Region. To the great team at AngioDynamics - congratulations on your new corporate headquarters, and I look forward to working with you to continue making the Capital Region a great place for business."

The Albany location offers 54,000-square-feet of space, is adjacent to I-87 off Exit 7 and can accommodate as many as 150 employees. It will allow for greater capacity at AngioDynamics' Queensbury facility so that it may properly serve as the company's manufacturing hub, as well as the central point in AngioDynamics' warehousing and distribution network.

The newly constructed building is designed to earn a LEED silver certification from the U.S. Green Building Council. To earn the designation, regional and recycled building materials were used, as well as high efficiency rooftop units, a well insulated building envelope, energy efficient lighting and water efficient fixtures in the restrooms.

AngioDynamics entered into an agreement to lease the space in July 2009 for a 10-year period, plus two five-year renewal options.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Company Contact:
AngioDynamics, Inc.
D. Joseph Gersuk, CFO
(800) 772-6446 x1608
jgersuk@AngioDynamics.com

Investor Relations Contacts:
EVC Group, Inc.
Doug Sherk/Jenifer Kirtland
(415) 896-2005
dsherk@evcgroup.com
jkirtland@evcgroup.com

Media Contact:
EVC Group, Inc.
Chris Gale/ Steve DiMattia
(646) 201-5431
cgale@evcgroup.com
sdimattia@evcgroup.com